Deals

Betta Pharmaceuticals Acquires Global Rights to SS202 Ultra‑Long‑Acting Monthly Growth Hormone from Gensciences – Deal Valued at Up to RMB 50 Million Plus Royalties
Betta PharmaceuticalsGensciences

Betta Pharmaceuticals Acquires Global Rights to SS202 Ultra‑Long‑Acting Monthly Growth Hormone from Gensciences – Deal Valued at Up to RMB 50 Million Plus Royalties

Betta Pharmaceuticals Co., Ltd. (SHE: 300558) and Hangzhou Gensciences Biopharmaceuticals Co., Ltd. announced a collaboration under which Betta Pharmaceuticals has acquired the global exclusive rights to the ultra‑long‑acting monthly growth…

Astellas Inks Exclusive Option and License Deal for Audax's DAX-044 – Up to USD 1.3 Billion to Back Tumor-Targeted IL-12 Immunotherapy

Astellas Inks Exclusive Option and License Deal for Audax’s DAX-044 – Up to USD 1.3 Billion to Back Tumor-Targeted IL-12 Immunotherapy

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
BiotechIPO

Luzhu Bio Files for Hong Kong IPO After RMB 4.42 Billion Valuation

FinanceMedical aesthetics

Youwe Bio’s Series B Financing to Advance Microneedle Technology Commercialization

IPOMicroPort NeuroTech

MicroPort NeuroTech Lists in Hong Kong with $43.3 Million IPO

CAR-TCell-therapy

Legend Biotech Collaborates with Trinity College Dublin on CAR-T Therapies for Solid Tumors

Show More